Cisplatin-based adjuvant chemotherapy in dogs with anal sac gland carcinoma
Aniruddha Banerjee, Arkaprabha Shee, Shashank Tripathi, Palash Biswas, Sagun Soren and Md. Mofijul Islam
Canine Anal Sac Gland Carcinoma is an uncommon skin neoplasm and highly invasive in character. The present study was conducted to find out whether adjuvant therapy of cisplatin would more effective than surgery alone in Canine Anal Sac Gland Carcinoma(ASGC). 30 pet dogs with naturally occurring ASGC were included in this study. The present study demonstrated that dogs received cisplatin adjuvant therapy have significantly less serum calcium level (X 2 =4.83 P<0.05), metastasis rate(X2 =5.75 P<0.05). and local recurrence rate (X 2 =5.19 P<0.05) than dogs had surgery alone. This study also revealed that cisplatin adjuvant therapy also significantly prolonged survival time in dogs (10.74 ± 0.35, P<0.05). In conclusion our result suggest that dogs received cisplatin adjuvant chemotherapy Anal Sac Gland Carcinoma showed more favourable prognosis than surgery alone.